Acid Suppression Therapy

Introduction to Acid Suppression

The British Society of Gastroenterology guidelines recommend PPIs as the first-line choice for symptomatic management of acid-related disorders, with a Grade A recommendation 1, 2, 3
A Cochrane review found that PPIs are more effective than H2 receptor antagonists for symptom control in patients with reflux disease, with an evidence grade of Ia 1, 2

PPIs have the best clinical profile for symptomatic management according to the British Society of Gastroenterology guidelines, with a Grade A recommendation 1, 2, 3

Tachyphylaxis develops within 6 weeks of ranitidine treatment, limiting its effectiveness for long-term use 4, 5
Standard doses of H2 antagonists like ranitidine reduce duodenal but not gastric ulcers when used with NSAIDs, according to the American College of Cardiology 6, 5
Ranitidine is less effective than PPIs for symptom relief and healing of erosive esophagitis 4

The FDA notes that H2 blockers like ranitidine do not interfere with clopidogrel's antiplatelet activity, unlike some PPIs, making it a consideration for patients on dual antiplatelet therapy 7
The American Academy of Pediatrics recommends starting with ranitidine 5-10 mg/kg/day divided in 2-3 doses for mild, intermittent GERD symptoms in pediatric patients 4

Long-term PPI use requires consideration of osteoporosis, GI infections, and pneumonia risk, according to the British Society of Gastroenterology 1, 2, 3
PPIs remain very safe overall, and these risks must be balanced against the significant benefits of superior acid suppression, according to the British Society of Gastroenterology 1, 2

The British Society of Gastroenterology guidelines recommend starting with pantoprazole 40 mg once daily for most acid-related disorders requiring treatment 1, 2, 3

Standard-dose ranitidine reduces duodenal ulcers but NOT gastric ulcers in NSAID users, according to pooled analysis of five randomized trials, as recommended by the American Gastroenterological Association 8, 9, 10
PPIs provide superior protection compared to ranitidine in H. pylori-positive patients, though differences are smaller in H. pylori-negative patients, as stated by the American College of Gastroenterology 8, 9, 10, 11
Ranitidine develops tolerance within 6 weeks of treatment, limiting its effectiveness for long-term use, which is a critical disadvantage not seen with PPIs, according to the National Institute of Diabetes and Digestive and Kidney Diseases 8, 9, 10
The American Association for the Study of Liver Diseases recommends H2 blocking agents or PPIs for stress ulcer prophylaxis in acute liver failure patients (Grade I, III evidence) 12, 13
When using pantoprazole with dasatinib, separate dosing by 12 hours as PPIs may reduce dasatinib absorption, as advised by the European Society for Medical Oncology 14
Both medications can be used in renal impairment, though this context requires dose adjustment considerations based on individual patient factors and severity of renal dysfunction, as recommended by the National Kidney Foundation 12